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Abstract
Objective. To investigate compliance, satisfaction, and preference in women using a transdermal contraceptive patch.
Methods. Women (18–46 years) from eight European countries used contraceptive patches (norelgestromin 6 mg,
ethinylestradiol 600 mg) for six, 4-week treatment cycles. Compliance, satisfaction, and preference were assessed after 3 and 6
cycles and study completion using self-report methods.
Results. Of the 778 participants, 36.8% (n¼287) used no contraception at baseline. The most common methods were oral
contraceptives (67.9%, n¼334) and barrier methods (21.5%, n¼106). Of oral contraception users, 63.5% (n¼212) were
satisﬁed or very satisﬁed with their previous method, but compliance was poor with 77.8% (n¼260) reporting missed doses.
After 3 and 6 cycles, 480% of all included women were satisﬁed or very satisﬁed with the patch. At study completion, most
participants (73.7%) reported a preference for the patch compared to their previous method. Of 4107 cycles, 3718 (90.5%)
were completed with perfect compliance. Two pregnancies occurred during this study, representing a Pearl Index of 0.63.
No new safety issues were identiﬁed and the patch was well tolerated.
Conclusion. Women were highly satisﬁed with transdermal contraception and preferred this form of family planning over
their previous method. Transdermal contraception represents a valuable addition to contraceptive options with potential to
offer high compliance and efﬁcacy.
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Introduction
Compliance and correct use of contraceptives is of critical
importance in the prevention of pregnancy. Minimizing the
frequency of dosing is one way of improving adherence with
hormonal contraception. Some nonhormonal contracep-
tives have been introduced to reduce the risk of ‘‘missing
pills,’’ e.g., the transdermal patch and the vaginal ring. The
ﬁrst and only transdermal contraceptive patch to receive
widespread regulatory approval, EVRA
1/ORTHO EVRA
1
(ethinylestradiol/norelgestromin), is a convenient approach
to contraception that has a similar efﬁcacy to oral contra-
ceptives,butwiththebeneﬁtof once-weeklyadministration.
Inaddition, transdermaldeliveryofcontraceptivehormones
providesanumberofdifferencescomparedtotheoralroute:
elimination of the variability in gastrointestinal absorption,
avoidance of the hepatic ﬁrst-pass metabolism, and preven-
tion of peaks and troughs in serum concentrations that are
seen with oral contraceptives [1,2].
The efﬁcacy of the contraceptive patch has been clearly
demonstrated in three Phase III studies; two of which were
randomized comparisons with an oral contraceptive. The
safety and tolerability proﬁle of the patch was shown to be
comparable to that of oral contraceptives [1,3–10].
Compliance as well as satisfaction with the contraceptive
patch has been shown to be signiﬁcantly better than with
oral contraceptives in a clinical trial setting [4,11]. In a large
clinical trial, North American women of all ages (18–45
years) were able to use the patch more consistently and
correctly, than the comparative oral contraception users
[12]. Another, more recent, comparative study that was
conducted in Europe and South Africa, found that, overall,
patch users had signiﬁcantly more cycles with perfect com-
pliance than oral contraception users (P50.001) [13]. The
patch users also reported a high level of satisfaction and
improvement in emotional and physical well-being, com-
pared to the oral contraception group [11,13].
The dosing regimen of the transdermal contraceptive
patch mimics that of most oral contraceptives: 21 days of
active hormones, followed by 7 days without hormones, but
with the advantage that the patch only requires a once-a-
week application for three consecutive weeks, followed by
one patch-free week. The patch may be applied to the upper
outer arm, lower abdomen, upper torso, or buttocks [14].
Results from three clinical trials in more than 3000
women have shown that efﬁcacy and cycle control are
similar with transdermal contraception to those reported for
oral contraceptives [3]. Early studies in women aged 18–45
Correspondence: A. J. Jakimiuk, Center for Reproductive Health, Institute of Mother and Child, Warsaw, Poland. E-mail: jakimiuk@yahoo.com
Gynecological Endocrinology, October 2011; 27(10): 849–856
ISSN 0951-3590 print/ISSN 1473-0766 online ª 2011 Informa UK, Ltd.
DOI: 10.3109/09513590.2010.538095years have shown that compliance with the weekly patch is
signiﬁcantly better than with a daily oral contraceptive
dosing regimen across all cycles and all age groups [12,15].
In contrast, compliance with the oral contraceptive was
signiﬁcantly related to age, ranging from 68% in younger
women aged less than 20 years, to 85% in women aged 40–
45 years [12]. It is hypothesized that the improved
compliance with the patch could result in fewer unintended
pregnancies compared to an oral contraceptive in a large
population [16].
As human behavior tends to be reinforced when
rewarded, satisfaction with a contraceptive method is
essential for long-term adherence, and depends mainly on
selecting the optimal contraceptive method [2].
In this context, satisfaction encompasses a number of
factors relating to the user’s experience, including ease of
use, acceptance by self and partner, tolerability, and
effectiveness. Women who are satisﬁed with their chosen
method of contraception are more likely to be compliant
with the regimen, hence optimizing contraceptive efﬁcacy.
The main objective of this pan-European study was to
evaluate women’s experience with transdermal contracep-
tion, focusing on compliance, satisfaction, and user
preference. The results of the Italian subgroup of this study
were already reported in 2009 [17]. This article provides an
overview of the results of the entire population that
participated in the study.
Methods
Study design
This open-label, single-arm study was conducted in
Belgium, Bulgaria, France, Ireland, Italy, Poland, Roma-
nia, and Russia. Participating women received contra-
ception via a patch (EVRA
1, Janssen-Cilag) for 24 weeks,
comprising six, 4-week treatment cycles.
The study was conducted in accordance with the
Declaration of Helsinki and subsequent revisions, local
ethics committee approval was obtained and all partici-
pants provided written informed consent.
Participants
Participants were women aged 18–46 years who had a
regular menstrual cycle occurring every 25–35 days (unless
using an implant, which was removed immediately before
the application of the patch. In case of injectable contra-
ceptives, the patch was applied 12 weeks – 12 weeks and 5
days after the last injection), were sexually active, and at risk
of pregnancy. Participants were required to have a normal
Pap smear within the 12 months before enrolment and a
negative urine pregnancy test at the screening visit, with
conﬁrmation of start of menses before application of the
ﬁrst patch. The main exclusion criteria for the study were as
follows: known contraindications to hormonal contracep-
tives; recent history of alcohol or substance abuse; skin
conditions associated with oily, irritated or damaged skin at
all potential application sites; and chronic use of barbitu-
rates, antiepileptics, rifampin, griseofulvin, or other hepatic
enzyme-inducing agents or systemic antibiotics.
Study medication
The 20 cm
2 patch contains norelgestromin 6 mg and
ethinylestradiol 600 mg. During each cycle, a patch was
worn for 1 week and replaced on the same day of the week
for three consecutive weeks. The patch could be placed on
the buttocks, abdomen, upper torso (with the exception of
the breasts), or the upper outer arm. The fourth week of
each cycle was patch-free.
Assessments
Participants visited the clinic for assessment at screening
(Visit 1), and at the end of Cycles 1 (Visit 2), 3 (Visit 3),
and 6 (Visit 4). Individuals were also contacted by
telephone on Day 1 of Cycle 1.
At screening, participants who were currently using a
method of contraception completed a standard set of
questions regarding their satisfaction with their method. At
the end of Cycles 3 and 6, participants completed the same
standard set of questions regarding their satisfaction with
the patch. In addition, at the end of Cycle 6 (or on early
withdrawal), participants were asked to compare the patch
with their previous method, if applicable, and about their
future contraceptive choice.
Satisfaction was assessed by a number of questions, each
evaluated on a 5-point scale. Questions included: (1)
Overall satisfaction (very dissatisﬁed, dissatisﬁed, neither
satisﬁed nor dissatisﬁed, satisﬁed, very satisﬁed); (2)
Convenience (very inconvenient, inconvenient, neither
convenient nor inconvenient, convenient, very conveni-
ent), (3) Worry about getting pregnant (all of the time,
most of the time, some of the time, a little of the time, none
of the time), and (4) Satisfaction with adhesion of the patch
(very dissatisﬁed, dissatisﬁed, neither satisﬁed nor dissa-
tisﬁed, satisﬁed, very satisﬁed). Women were also asked to
state how strongly they agreed or disagreed with a number
of statements, again assessed on a 5-point scale (strongly
disagree, disagree, neither agree nor disagree, agree,
strongly agree): I easily incorporated the method into my
lifestyle; I am satisﬁed with the frequency – once a week; I
feel secure that the patch works; The patch has improved
my sex life; My partner accepts the patch.
Quality of life was assessed at screening and at the end of
Cycles 3 and 6 using the validated Short Form 12 (SF-12)
instrument [18]. Compliance was assessed by diary cards.
Perfect compliance was deﬁned on the basis of ﬁve criteria:
ﬁrst patch to be applied on the ﬁrst day of menses; patch to
be worn for not more than 7 days; continuous patch use for
21 days; no interval between successive patches; a patch-
free interval of 1–7 days in the 4th week of the cycle.
Safety was assessed at each postscreening contact (i.e.,
study visits and telephone contact), and investigators
assessed any possible relationship to the contraceptive patch.
Urine pregnancy tests were carried out at screening, at the
end of the study, and at any visit if pregnancy was suspected.
Efﬁcacy was assessed using the Pearl index (i.e., the
number of pregnancies per 100 woman–years of use).
Analysis
The primary aims of the study were to assess the level of
satisfaction with the patch and, where applicable, to
compare satisfaction with the patch with the subject’s
previous contraceptive method.
As the results were to be reported descriptively, no
formal sample size calculation was performed. It was
expected that the inclusion of approximately 1000 subjects
would be sufﬁcient to allow for various subgroup analyses.
Demographic variables, obstetric and gynecological
history, primary contraceptive information at baseline,
850 A. J. Jakimiuk et al.and endpoint parameters were tabulated. Between-group
comparisons were made using the Wilcoxon two-sample
test for ordinal and interval variables and Fisher’s exact test
for nominal variables. Within-group comparisons of shifts
versus baseline were made using the Wilcoxon signed rank
test. All statistical comparisons were made using two-tailed
analyses with P 0.05 required for signiﬁcance.
The statistical analyses were performed using SAS
version 9.1 (SAS Institute, 1999–2001). The SF-12
(version 1) physical component summary (PCS) and
mental component summary (MCS) were calculated
according to Ware [19].
Results
Participants
From the eight European countries involved, 105 active
sites participated to the trial (40 in France, 23 in Italy, 11 in
Romania, 9 in Belgium, 8 in Poland, 7 in Ireland, 4 in
Bulgaria, and 3 in Russia), and in total, 820 women were
screened for the study. Of these, 38 did not receive study
treatment and were therefore not included in the analysis.
Two other participants were lost to follow-up after Visit 1
(it was not clear whether they even used the patch at all). Of
the 780 women who received at least one patch (207 in
Italy, 147 in France, 103 in Romania, 100 in Poland, 86 in
Belgium, 61 in Bulgaria, 58 in Russia, and 18 in Ireland),
two did not perform a ﬁnal visit, meaning that endpoint
data were available for 778 participants. Baseline char-
acteristics are shown in Table I. Almost half of the women
had previously been using oral contraception. The study
was completed by 642 (82.3%) of the 780 women who
received at least one transdermal patch. The most common
reasons for withdrawal from the study were AEs (n¼55,
39.9%), withdrawal of consent (n¼31, 22.5%), and lost to
follow-up (n¼22, 15.9%).
Satisfaction with and preference of contraceptive method
For the women who were using a contraceptive method at
baseline (n¼482), overall satisfaction at baseline is shown
in Figure 1. Women were generally more satisﬁed with oral
contraception (63.5% of users) than with barrier methods
(31.2% of users).
Overall satisfaction with transdermal contraception in
the whole study group is shown in Figure 2.
In general, women who were using a contraceptive
method at baseline reported higher satisfaction with the
patch than with their previous contraceptive method. At
baseline, 54.4% of women using contraception were
satisﬁed or very satisﬁed with their chosen method.
Compared to the start of the study, after three cycles (Visit
3), 83.0% of these women were satisﬁed or very satisﬁed
with the patch, and after six cycles (Visit 4), the percentage
increased to 87.5%. Considering the subset of women
currently using a contraceptive method at baseline, the
largest change was seen with regard to the participants’
satisfaction with the once-a-week frequency of patch
application (Figure 3), which improved by 1.4 points on
a 5-point scale compared with their previous contraceptive
method (P¼0.0001). There was no signiﬁcant change in
participants’ response to the question about improvement
in their sexual life or the partner’s acceptance of the patch.
Table II presents the most prominent improvements
compared to baseline, seen on individual questions relating
to convenience, worrying about pregnancy, ease of incor-
poration into lifestyle, satisfaction with the once-a-week
frequency, feeling of security, and overall satisfaction of the
patch. This table compares the patch evaluation of the whole
study group (including naive women to contraceptive meth-
ods) versus women currently using a method at baseline.
Considering the subset of women currently using a
contraceptive method at baseline, 87% of participants
reported they were satisﬁed or very satisﬁed regarding the
adhesion of the patch at the end of Cycle 6. At the end of
the last cycle, almost 90% recorded that the patch was
convenient or very convenient, 92% felt secure that the
patched worked, and 81% (strongly) agreed that their
partner accepted the patch.
The questions for Visit 1 are referred to the method used
at baseline, for the other visits they are referred to the
patch.
Most participants using contraception at baseline or
having used an anticonceptive method in the 3 months
prior to study start, reported a preference for the patch over
their previous method (Figure 4), regardless of the type of
contraception; 68.6% of women using oral contraceptives
and 86.2% using barrier methods at baseline reported a
preference or strong preference for the patch. The reasons
most often cited for the preference of the patch were
convenience (45.4%), ease of use/simplicity (28.8%) and
fewer side effects (17.5%).
Of the women who were not using a contraceptive method
at baseline of the study (n¼287), 83.5% and 90.7% also
were satisﬁed or very satisﬁed with the patch at the end of
Visits 3 and 4, respectively. After three cycles, 83.9% found
thepatchconvenientorveryconvenient,88.6%incorporated
the method easily into their lifestyle, and 83.2% felt secure
that the patch worked. After six cycles, these percentages
increased to more than 90% for these aspects. This
satisfaction was reﬂected to a lesser extent in the choice for
Table I. Baseline characteristics.
N¼780 mean+SD, unless stated
Age, years 28.4+6.2
Height, cm 165.0+6.1
Weight, kg 58.9+9.2
BMI530 kg/m
2, n (%) 763 (97.8)
BMI 30 kg/m
2, n (%) 17 (2.2)
Pregnancy history, n (%)
0 358 (45.9)
1 168 (21.5)
2 151 (19.4)
42 103 (13.2)
Delivery history, n (%)
0 430 (55.1)
1 184 (23.6)
2 139 (17.8)
42 27 (3.5)
Contraception used in the previous 3 months, n (%)
None 243 (31.2)
Oral 354 (45.4)
Barrier 133 (17.1)
Other* 50 (6.4)
Mean duration of previous
contraceptive use, days
861.6+1208
BMI, body mass index.
*Includes intrauterine device, implants, injection, withdrawal,
fertility awareness, vaginal ring, spermicide, postcoital contra-
ception (emergency contraception), and abstention.
Contraceptive patch 851the future method because 48.0% indicated they would use
the patch in future, 14.3% said they would use oral
contraceptives and 22.0% said they would not use any
contraceptive method in the future. Overall, 73.7% of the
participants in the entire study group had a preference for the
patch compared to their previous contraceptive method at
the ﬁnal visit, and if given the choice, they would also
continue using this method of contraception.
Compliance
At baseline, self-reported compliance with oral contra-
ceptives was poor. Only 22.2% of women stated that they
never forgot to take their contraception, with 35.9%
reporting they forgot to use their contraceptive ‘‘some,’’
‘‘most’’ or ‘‘all of the time.’’ Just over half of oral
contraceptive users (52.5%) considered this to be at least
a convenient method (42.0% convenient; 10.5% very
convenient).
Based on participants’ diaries, 3718 of 4107 recorded
cycles (90.5%) were completed with perfect compliance
with patch use. Despite the stringency of the criteria for
perfect compliance, 67.7% of participants were fully
compliant with all their cycles. The most common reason
for not achieving perfect compliance was that a patch was
not on the skin for exactly 21 consecutive days (6.0%). The
mean compliance score (calculated for each individual as
Figure 1. Overall satisfaction with contraception used at baseline.
Figure 2. Overall satisfaction with the patch after 3 (Visit 3) and 6 cycles (Visit 4) in the whole study group.
852 A. J. Jakimiuk et al.the number of cycles with perfect compliance divided by
the total number of cycles) was 86.2% (+26.4 SD). The
main reasons for patch removal were scheduled change
(93.0%), patch partially lifted off (3.3%) and patch fell off
(2.9%). Four women (2.9%) were withdrawn from the
study as a result of poor compliance.
Quality of life
Mean scores on the Physical Component Summary (PCS)
of the SF-12 remained unchanged throughout the study
(baseline, 54.0+4.7 SD; end of Cycle 6, 54.2+4.3 SD).
Scores on the Mental Component Summary (MCS)
increased from 50.5+7.8 at baseline to 52.0+7.2 SD at
the end of Cycle 3 and 52.4+7.3 SD at the end of Cycle 6.
No statistically signiﬁcant changes in PCS were observed,
compared to baseline. However, the mean changes from
baseline to the end of Cycles 3 and 6 in MCS were
statistically signiﬁcant (P¼0.0001, in both cases), but
these small changes were unlikely to have been of mean-
ingful clinical relevance.
Safety
During the 24-week study period, treatment emergent
adverse events (AEs) were reported by 42.3% of partici-
pants. During the ﬁrst cycle, 57.9% of these AEs started
and most (45.6%) of these AEs also stopped during this
cycle. The frequency of occurrence tended to decrease
over time; 12.8% of women reported AEs in the 3rd cycle,
whereas 6.9% in the 6th cycle. The most common AEs
were spotting between menses (9.0% of participants),
breast pain (8.2%) and headache (6.5%). Most AEs were
considered mild (52.9%) or moderate (36.2%) in severity
and were not or doubtfully (35.0%), possibly (23.0%),
probably (20.4%), or very likely (21.7%) related to the use
of the transdermal patch. The application of the patch was
permanently stopped in 12.8% of AEs. Most AEs (90.4%)
were resolved before the end of the study. Fifty-ﬁve
(7.1%) participants dropped-out of the study due to
an AE.
Three women experienced a serious adverse event
(SAE) during the study, which required hospitalization
(radiculitis, bartholinitis, and aggravated Graves-Basedow
disease with increased exophthalmia and diplopia); how-
ever, none of them were considered related to the
Figure 3. Satisfaction questions: mean scores at each visit for the subset of women currently using a contraceptive method at baseline.
Table II. Signiﬁcant improvements on individual questions.
Baseline (%) Visit 3 (%) Visit 4 (%)
(Prev.
method)
n¼491
(Patch)
n¼759
(Patch)
n¼659
(Very) Convenient 45.5 83.1 89.2
Worry about pregnancy:
all/most of the time
10.6 4.6 3.4
(Very) Easily incorporated
into lifestyle
72.7 89.0 93.8
(Very) Satisﬁed with
frequency of dosing
44.3 91.3 95.7
Feel (very) secure 79.4 85.9 92.3
Overall (very) satisﬁed 54.4 81.3 88.2
The percentages at baseline are referred to women currently using
a contraception method; percentage at Visits 3 and 4 are referred
to the whole study group.
n¼number of subjects at the speciﬁed visit.
Two-sided Wilcoxon signed rank test.
Contraceptive patch 853transdermal patch, and all participants recovered from
these SAEs.
No clinically relevant deviations were observed regarding
weight change or vital signs.
At baseline, participants mean weight was 58.9 kg
(+9.2 kg SD).
At Cycle 6, a mean weight increase of 0.4 kg (+2.5 kg
SD) versus baseline was observed (P¼0.0001), representing
am e a ni n c r e a s eo f0 . 8 %( +4.2% SD). Women aged less
than 21 years, 21–25 years, and 31–40 years, experienced a
mean weight gain of 0.5–0.6 kg, whereas women aged 26–30
years, and 41–50 years, only gained 0–0.1 kg. No clear
differences in weight were seen between participants who
previously used contraception and those who did not.
At baseline, the participant’s mean BMI was 21.6 kg/m
2
(+3.2 kg/m
2 SD). At Cycle 6, a mean BMI increase of 0.2
kg/m
2 (+0.9 kg/m
2 SD) versus baseline was noted
(P¼0.0001), also representing a mean increase of 0.8%
(+4.0% SD).
No statistically signiﬁcant differences from baseline were
reported regarding pulse, systolic blood pressure, and
diastolic blood pressure.
Efﬁcacy
Two pregnancies occurred during this study, representing
a Pearl index (estimate of the number of pregnancies per
100 woman-years of use) of 0.63.
Discussion
It is widely accepted that compliance, and thus efﬁcacy, is
generally higher in clinical studies than it is in the ‘real
world’ setting. Compliance is, however, likely to be
increased if individuals are highly satisﬁed with their
chosen method of contraception. In this context, our data
showing that women switching to the patch were more
likely to say they were ‘‘satisﬁed’’ or ‘‘very satisﬁed’’ with
this contraceptive method are of interest. Women using
oral contraceptives at baseline tended to be satisﬁed with
this method, but even amongst this group, over two-thirds
of participants expressed a preference for the patch by the
end of the 24-week study period. A motivating factor for
women to enter the study was likely to have been some level
of dissatisfaction with their current method of contra-
ception, thus some improvement in satisfaction scores was
to be expected.
The convenience and ease of use of the patch were cited
as the most important factors contributing to preference
over previous forms of contraception. Interestingly, almost
20% of participants cited fewer AEs as their reason for
preferring the patch. The high level of subject satisfaction
from patient questionnaires was accompanied by positive
ﬁndings in the SF-12 Quality of Life (QoL) instrument.
While the mean scores on the PCS of the SF-12 remained
unchanged throughout the study, statistically signiﬁcant
changes in the mean MCS scores were observed at the
end of Cycles 3 and 6. However, these changes were small
and unlikely to have meaningful impact on overall QoL
[19]. Given the study population comprised generally
healthy women with already robust baseline QoL scores,
satisfaction in contraception choice is unlikely to shift
overall QoL. Nevertheless, the improved satisfaction, and
preference of the patch over previous method indicates a
generally positive experience for women using the contra-
ceptive patch and this should not be ignored as an
important factor in women’s physical and mental health
and well-being.
Figure 4. Personal preference between the patch and the previous method. Previous method means either the method currently used at
baseline or that had been used in the 3 months prior to study entry.
854 A. J. Jakimiuk et al.The data obtained in our study are consistent with
those from previous studies of participant satisfaction
and well-being while using the contraceptive patch.
Signiﬁcantly more patch users were very satisﬁed with
their study regimen compared with the oral group, and
there was a weak correlation between overall satisfaction
and both mental and physical well-being [13]. Data from
our study were obtained from eight European countries,
while those of the previously cited were from 65 centers
in Europe and South Africa, indicating that the results
a r en o tn e c e s s a r i l yc u l t u r a l l ys p e c i ﬁ c .F u r t h e r m o r e ,
similar results have been reported recently in a Canadian
trial, in which 91% of those who completed the nine-
cycle study were satisﬁed with the patch, and about 75%
of those who completed all nine cycles expressed a
preference for the patch over their previous contra-
ception [20].
As might be expected from the high level of satisfaction
with treatment, compliance in the study was high (90.5%).
This supports other ﬁndings that have shown transdermal
contraception to be associated with a signiﬁcantly greater
proportion of perfect cycle compliance than oral contra-
ceptives [13,16,21,22]. One of the main factors known
to affect compliance is the inconvenience of frequent
dosing regimens. Indeed, reductions in dose frequency
have been shown to improve compliance in a number of
therapeutic areas, leading to improvements in outcomes
[23]. In a meta-analysis conducted by the Cochrane
Collaboration of studies involving the contraceptive patch,
the authors reported that compliance was signiﬁcantly
greater with the weekly patch than with daily oral
contraception (odds ratio: 2.1; 95% Conﬁdence Interval:
1.8–2.3) [24].
Patch contraception was generally well tolerated in our
study, which likely contributed to the high levels of
satisfaction and compliance. Although more than 40% of
participants reported AEs, most events started and stopped
during the ﬁrst cycle. It should also be noted that AEs
tended to be more prevalent in early cycles, which is
consistent with ﬁndings in previous studies. During the
study, three women experienced SAEs which required
hospitalization (radiculitis, bartholinitis, and aggravated
Graves-Basedow disease with increased exophthalmia and
diplopia); however, none of them were considered related
to the transdermal patch, and all participants recovered
from these SAEs. Two pregnancies occurred during this
study, yielding a Pearl index of 0.63, which is consistent
with previous studies [3,15,22].
In conclusion, women generally have a high level of
satisfaction with transdermal contraception and expressed
a preference for this form of family planning over their
previous method. This method thus represents a valuable
addition to contraceptive options with the potential to offer
high compliance and thus efﬁcacy.
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